<DOC>
	<DOCNO>NCT01516879</DOCNO>
	<brief_summary>To evaluate efficacy , safety , tolerability 52 week subcutaneous ( SC ) evolocumab ( AMG 145 ) compare placebo add assign background lipid-lowering therapy .</brief_summary>
	<brief_title>Durable Effect PCSK9 Antibody CompARed wiTh placEbo Study</brief_title>
	<detailed_description>Eligible participant screen central laboratory low-density lipoprotein cholesterol ( LDL-C ) value ≥ 75 mg/dL ( 1.9 mmol/L ) instruct follow National Cholesterol Education Program ( NCEP ) Adult Treatment Panel III ( ATP ) Therapeutic Lifestyle Changes ( TLC ) diet assign 1 follow 4 background lipid-lowering therapy 4-week stabilization period base upon screen LDL-C distance individual 's required goal stipulate NCEP ATP III risk category : 1. drug therapy require - diet alone 2. low dose drug therapy require - diet plus atorvastatin 10 mg orally ( PO ) daily ( QD ) 3. high dose drug therapy require - diet plus atorvastatin 80 mg PO QD 4. maximal drug therapy require - diet plus atorvastatin 80 mg PO QD plus ezetimibe 10 mg PO QD . If participant meet entry criterion end lipid stabilization period randomize 2:1 receive evolocumab 420 mg placebo subcutaneously month 52 week addition background therapy .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subject provide informed consent . Fasting LDLC ≥ 75 mg/dL meeting follow LDLC value background lipidlowering therapy : &lt; 100 mg/dL subject diagnose coronary heart disease ( CHD ) CHD risk equivalent &lt; 130 mg/dL subject without diagnosed CHD CHD risk equivalent OR maximal background lipidlowering therapy define atorvastatin 80 mg PO QD ezetimibe 10 mg PO QD Fasting triglycerides ≤ 400 mg/dL New York Heart Association ( NYHA ) IIIV heart failure , last known leave ventricular ejection fraction &lt; 30 % Uncontrolled cardiac arrhythmia Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month prior randomization , type 1 diabetes , newly diagnose poorly control type 2 diabetes Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>Raised Cholesterol</keyword>
</DOC>